Halozyme Acquires Antares Pharma for $960M
April 13, 2022
Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.
- Buyers
- Halozyme Therapeutics, Inc.
- Targets
- Antares Pharma, Inc.
- Sellers
- Antares shareholders
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.